Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Recent genetic and proteomic studies demonstrate that clusterin/apolipoprotein-J is associated with risk, pathology, and progression of Alzheimer’s disease (AD). Our main aim was to examine associations between plasma clusterin concentration and longitudinal changes in brain volume in normal aging and mild cognitive impairment (MCI). A secondary objective was to examine associations between peripheral concentration of clusterin and its concentration in the brain within regions that undergo neuropathological changes in AD. Non-demented individuals (N = 139; mean baseline age 70.5 years) received annual volumetric MRI (912 MRI scans in total) over a mean six-year interval. Sixteen participants (92 MRI scans in total) were diagnosed during the course of the study with amnestic MCI. Clusterin concentration was assayed by ELISA in plasma samples collected within a year of the baseline MRI. Mixed effects regression models investigated whether plasma clusterin concentration was associated with rates of brain atrophy for control and MCI groups and whether these associations differed between groups. In a separate autopsy sample of individuals with AD (N=17) and healthy controls (N=4), we examined the association between antemortem clusterin concentration in plasma and postmortem levels in the superior temporal gyrus, hippocampus and cerebellum. The associations of plasma clusterin concentration with rates of change in brain volume were significantly different between MCI and control groups in several volumes including whole brain, ventricular CSF, temporal gray matter as well as parahippocampal, superior temporal and cingulate gyri. Within the MCI but not control group, higher baseline concentration of plasma clusterin was associated with slower rates of brain atrophy in these regions. In the combined autopsy sample of AD and control cases, representing a range of severity in AD pathology, we observed a significant association between clusterin concentration in the plasma and that in the superior temporal gyrus. Our findings suggest that clusterin, a plasma protein with roles in amyloid clearance, complement inhibition and apoptosis, is associated with rate of brain atrophy in MCI. Furthermore, peripheral concentration of clusterin also appears to reflect its concentration within brain regions vulnerable to AD pathology. These findings in combination suggest an influence of this multi-functional protein on early stages of progression in AD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“…recent genome-wide association studies (GWAS) demonstrating associations between polymorphic variation in the clusterin gene (CLU) and risk of AD (Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010), these findings suggest a potential role for both the CLU gene and clusterin…”
Self-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900 · cited 1×
“Given that a significant proportion of elderly control subjects without cognitive impairment already harbor AD pathology, such as Aβ deposition in the brain (Savva et al., 2009), it is unlikely that this strategy will yield biomarkers accurately reflecting early neuropathology.”
BackgroundApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 2×
“While we have not addressed the precise mechanisms underlying this association, several lines of evidence suggest biological roles for clusterin in pathways relevant to AD pathogenesis, including amyloid clearance, complement modulation and apoptosis (DeMattos et al., 2004; DeMattos et al., 2002; French et al., 1994;…”
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Self-citationDeMattos, R. B., O'dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A. K., Bales, K. R., Paul, S. M., Aronow, B. J., & Holtzman, D. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162228299 · Cited by 359
Plasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220 · cited 2×
“Our finding of an association between plasma clusterin concentration and disease severity in AD was recently replicated in an independent study by Schrijvers et al. (2011).”
ResultClusterin facilitates in vivo clearance of extracellular misfolded proteins
Wyatt, A. R., Yerbury, J. J., Berghofer, P., Greguric, I., Katsifis, A., Dobson, C. M., & Wilson, M. R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0684-8 · Cited by 145
Giannakopoulos, P., Kövari, E., French, L. E., Viard, I., Hof, P. R., & Bouras, C. (1998) · Acta Neuropathologica · doi:10.1007/s004010050815 · Cited by 90 · cited 1×
“Consistent with this hypothesis, a previous postmortem study suggested a neuroprotective role for clusterin in brain regions vulnerable to AD pathology (Giannakopoulos et al., 1998).”
Result
Cited by
Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models
Bernal-Rusiel, J. L., Greve, D. N., Reuter, M., Fischl, B., & Sabuncu, M. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.10.065 · Cited by 360
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
Self-citationComplement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204
“identified as a genetic determinant of AD [217] and plasma CLU levels were associated with atrophy of the entorhinal cortex and clinical progression of the disease [218] as well as with longitudinal brain atrophy in MCI patients [219].”
BackgroundDeveloping novel blood‐based biomarkers for Alzheimer's disease
Snyder, H. M., Carrillo, M. C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., Mielke, M. M., O'Bryant, S., Sarasa, M., Sj⊘gren, M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.007 · Cited by 177
“In addition, because the peripheral blood has no direct contact with the brain, CSF markers of neurodegeneration may not be present in the blood or at detectable levels, making it difficult to apply correlating CSF biomarker findings to the blood.”
BackgroundSelf-citationThe Role of Clusterin in Alzheimer’s Disease: Pathways, Pathogenesis, and Therapy
Yu, J.-T., & Tan, L. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8237-1 · Cited by 174
“However, within the mild cognitive impairment (MCI), higher baseline concentration of plasma clusterin was associated with slower rates of brain atrophy in these regions including whole brain, ventricular CSF, temporal gray matter as well as parahippocampal, superior temporal, and cingulate gyri [50].”
Bernal-Rusiel, J. L., Reuter, M., Greve, D. N., Fischl, B., & Sabuncu, M. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.049 · Cited by 125
“…et al., 2011; Schuff et al., 2010; Schumann et al., 2010; Sidtis et al., 2010; Sluimer et al., 2008; Sluimer et al., 2009; Sullivan et al., 2011; Thambisetty et al., 2011; Thambisetty et al., 2010; Whitwell et al., 2011; Whitwell et al., 2007), most LNI studies have either focused on a small…”
BackgroundLacour, A., Espinosa, A., Louwersheimer, E., Heilmann, S., Hernández, I., Wolfsgruber, S., Fernández, V, Wagner, H., Rosende-Roca, M., Mauleón, A., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.18 · Cited by 101
Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
Kiddle, S. J., Thambisetty, M., Simmons, A., Riddoch-Contreras, J., Hye, A., Westman, E., Pike, I., Ward, M., Johnston, C., Lupton, M. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044260 · Cited by 100
“hippocampi, and the thickness of the left and right entorhinal cortices were used, as these regions are known to be important in AD pathology [12].”
Self-citationThe Role of Clusterin in Amyloid-β–Associated Neurodegeneration
Desikan, R. S., Thompson, W. K., Holland, D., Hess, C. P., Brewer, J. B., Zetterberg, H., Blennow, K., Andreassen, O. A., McEvoy, L. K., Hyman, B. T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4560 · Cited by 79
Martiskainen, H., Viswanathan, J., Nykänen, N.-P., Kurki, M., Helisalmi, S., Natunen, T., Sarajärvi, T., Kurkinen, K. M. A., Pursiheimo, J.-P., Rauramaa, T., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.003 · Cited by 70
Cavedo, E., Lista, S., Khachaturian, Z., Aisen, P., Amouyel, P., Herholz, K., Jack Jr, C. R., Sperling, R., Cummings, J., Blennow, K., et al. (2014) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2014.32 · Cited by 67
“Moreover, prior work has suggested that blood-based biomarkers can be utilized for the identification of AD-based endophenotypes (17, 167, 178) with additional work needed to determine if these endophenotypes can predict which groups of patients are more likely to respond to specific interventions (165).”
BackgroundHigh-density lipoprotein-related cholesterol metabolism in Alzheimer's disease
Pedrini, S., Chatterjee, P., Hone, E., & Martins, R. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15170 · Cited by 22
Metadata
- Authors
- Thambisetty, M., An, Y., Kinsey, A., Koka, D., Saleem, M., Gϋntert, A., Kraut, M., Ferrucci, L., Davatzikos, C., Lovestone, S., & Resnick, S. M.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 59
- Issue
- 1
- Pages
- 212-217
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2132437915
- Cited by
- 148
- References
- 10
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.